CIK 0000875320
- Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 043039129
- Phone
- +1 617-341-6393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $15,378,206
- in 4 filings, $15.4M under 10b5-1 plans
Net −$15,378,206. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-10 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Sale | −185 | $292.68 | $54K | 56,174 |
| 2023-03-10 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Sale | −27 | $293.61 | $8K | 56,147 |
| 2023-03-10 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Sale | −102 | $294.94 | $30K | 56,045 |
| 2023-02-27 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale | −283 | $287.20 | $81K | 56,876 |
| 2023-02-27 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale | −51 | $288.33 | $15K | 56,825 |
| 2023-02-27 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale | −20 | $289.29 | $6K | 56,805 |
| 2023-02-27 | Arbuckle Stuart A EVP, COO | Sale | −3,834 | $287.16 | $1.1M | 57,756 |
| 2023-02-27 | Arbuckle Stuart A EVP, COO | Sale | −400 | $287.59 | $115K | 57,356 |
| 2023-02-27 | Arbuckle Stuart A EVP, COO | Sale | −800 | $288.92 | $231K | 56,556 |
| 2023-02-27 | Ambrose Kristen SVP & Chief Accounting Officer | Sale | −982 | $287.25 | $282K | 7,528 |
| 2023-02-27 | Ambrose Kristen SVP & Chief Accounting Officer | Sale | −183 | $288.68 | $53K | 7,345 |
| 2023-02-27 | Ambrose Kristen SVP & Chief Accounting Officer | Sale | −42 | $289.63 | $12K | 7,303 |
| 2023-02-27 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −3,636 | $287.23 | $1.0M | 32,640 |
| 2023-02-27 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −300 | $288.74 | $87K | 32,340 |
| 2023-02-27 | ALTSHULER DAVID EVP, Global Research and CSO | Sale | −302 | $289.60 | $87K | 32,038 |
| 2023-02-24 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Shares withheld for taxes | −3,308 | $289.12 | $956K | 58,133 |
| 2023-02-24 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Shares withheld for taxes | −3,308 | $289.12 | $956K | 57,159 |
| 2023-02-24 | Sanna Bastiano EVP, Cell & Genetic Therapies | Shares withheld for taxes | −3,970 | $289.12 | $1.1M | 52,014 |
| 2023-02-24 | Sachdev Amit EVP, Chief Patient Officer | Shares withheld for taxes | −2,468 | $289.12 | $714K | 66,518 |
| 2023-02-24 | LEIDEN JEFFREY M Executive Chairman | Shares withheld for taxes | −13,730 | $289.12 | $4.0M | 48,349 |
Page 33 of 40 · 781 trades